Peter Kristensen was elected to the Board of Directors in 2024 and is regarded as an independent board member.
Special competencies
Peter has more than 30 years of drug development and regulatory experience from Novo Nordisk, as Senior External Advisor with McKinsey & Co and as an independent consultant. At Novo Nordisk, Peter started as a research scientist, headed the development of Victoza (liraglutide) and was for 10+ years Senior Vice President of drug development, project management and global clinical operations.
Current positions
Independent consultant.
Education
Peter has a Medical Degree and a Medical Doctorate from University of Copenhagen, an E*MBA from SIMI (today part of CBS Executive) and is a member of the Danish Academy of Technical Sciences.
Nationality
Danish
